1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Anorexia - Market Insight, Epidemiology And Market Forecast - 2032

Anorexia - Market Insight, Epidemiology And Market Forecast - 2032

  • May 2022
  • 107 pages
  • ID: 6276111
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Anorexia nervosa-Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the anorexia nervosa, historical and forecasted epidemiology as well as the anorexia nervosa market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The anorexia nervosa market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM anorexia nervosa market size from 2019 to 2032. The Report also covers current anorexia nervosa treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019–2032

Anorexia nervosa Disease Understanding and Treatment Algorithm

Anorexia nervosa Overview
Anorexia nervosa (AN) is an eating disorder characterized by weight loss or lack of appropriate weight gain in growing children; difficulties maintaining an appropriate body weight for height, age, and stature; and, in many individuals, distorted body image. People with anorexia generally restrict the number of calories and the types of food they eat.
This disorder is characterized by deliberate weight loss, induced and sustained by the patient. It occurs most commonly in adolescent girls and young women, but adolescent boys and young men may also be affected, as many children approaching puberty and older women up to the menopause. The disorder is associated with specific psychopathology whereby a dread of fatness and flabbiness of body contour persists as an intrusive, overvalued idea, and the patients impose a low weight threshold on themselves. There is usually under nutrition of varying severity with secondary endocrine and metabolic changes and disturbances of bodily function. The symptoms include restricted dietary choice, excessive exercise, induced vomiting and purgation, and use of appetite suppressants and diuretic
Eating disorders are not a choice but are serious mental illnesses and can significantly impact all aspects of a person’s life – physical, emotional, and social. The earlier an eating disorder is identified and a person can access treatment, the greater the opportunity for recovery or improved quality of life.
Anorexia Nervosa Diagnosis
No objective test—such as bloodwork or an X-ray—can definitively point to an eating disorder. Instead, a doctor makes the diagnosis based on a person’s symptoms. To diagnose anorexia, the doctor will ask about the person’s symptoms, and they may also ask family members and other loved ones about their observations. If a doctor believes that a person has anorexia, they will attempt to diagnose the type. One type primarily involves restricting food intake, while another involves episodes of overeating and purging. If the person has experienced at least one of these episodes in the past 3 months, the doctor will likely diagnose binge eating and purging anorexia.
Diagnostic instruments in the form of questionaires are used. Few of them are as follows:
• Structured Inventory for Anorexic and Bulimic Eating Disorders Self-Report (SIAB-S)
• Munich Eating and Feeding Disorder Questionnaire (Munich ED-Quest)
• Eating Disorder Examination-Questionnaire for children (ChEDE-Q)
• The SCOFF questionnaire

Continued in the report…..

Anorexia nervosa Treatment
Treatment for anorexia must address both psychological and physical problems. The treatment team should include a mental health professional and a primary care doctor.
Successful treatment usually includes continuous medical care, regular therapy, nutritional counseling, and medication. Although certain antidepressants are sometimes used to treat anorexia, they are not always effective, and no medication is FDA approved to treat it. Doctors should pay attention to bone loss, electrolyte levels in the blood, and heart function. Psychologists and other mental health professionals can help a person let go of self-destructive thoughts and behaviors and adopt a more positive outlook. Support groups of other recovering anorexics -- when properly moderated by a mental health professional -- can also be very helpful. Treatment usually is successful, but it does not work overnight. Long-term psychological and medical attention usually is needed.
Continued in the report…..

Anorexia nervosa Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of anorexia nervosa, diagnosed prevalent cases of anorexia nervosa and gender-specific diagnosed prevalent cases of anorexia nervosa scenario of anorexia nervosa in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Key Findings
• Total prevalent cases of anorexia nervosa in the 7MM were found to be approximately 1,692,817 in 2021. These cases are expected to increase by 2032 at a CAGR of 0.3% during the study period (2019–2032).
• Among 7MM, the United States has the highest prevalent cases of anorexia nervosa with 703,497 cases in 2021.
• The total diagnosed prevalent cases of anorexia nervosa in the 7MM were observed to be 812,552 in 2021. These cases are expected to increase during the study period (2019–2032).
• Among the European countries, Germany had the highest diagnosed prevalent population of Anorexia nervosa with 86,928 cases, followed by the UK with 69,732 cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent population.
• In Japan, 128,408 diagnosed prevalent cases of anorexia nervosa were recorded in the year 2021.
• As per assessment, for anorexia nervosa, the gender-specific distribution of the disease suggests females at a higher count with 763,335 cases in the 7MM, in 2021.

Anorexia nervosa Epidemiology
The epidemiology segment also provides the anorexia nervosa epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Anorexia nervosa Drug Chapters
The drug chapter segment of the anorexia nervosa report encloses the detailed analysis of anorexia nervosa marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the anorexia nervosa clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.

Anorexia nervosa Emerging Drugs
Psilocybin: COMPASS Pathways
Psilocybin is a serotonin 2 receptor agonist, being developed by COMPASS Pathways, for treatment-resistant depression, including major depressive disorder, depressive disorders, bipolar depression, body dysmorphic disorder (somatoform disorders in developmental table), and anorexia nervosa. It is an active ingredient in some species of mushrooms, often referred to as ‘magic mushrooms. Currently, a Phase II trial is expected to complete in 2022 showing the effect of psilocybin-assisted psychotherapy in patients with AN.
Ketamine: Homeostasis Therapeutics, LLC
Ketamine has rapid antidepressant effects, which are hypothesized to occur via increases in glutamate, with sequelae including increased neuroplasticity, neurogenesis, and synaptogenesis. It is an N-methyl-D-aspartate receptor (NMDAr) antagonist, recently been approved for treatment-resistant depression, exerting rapid and robust antidepressant effects. It is now being investigated for several indications, including obsessive-compulsive, post-traumatic, and substance use disorder, and shows trans diagnostic potential for EDs, particularly among clinical nonresponders.
Products detail in the report…
List of products to be continued in the report…

Anorexia nervosa Market Outlook
Anorexia Nervosa (AN) has a diverse genetic disposition as well as is being determined by life phases such as puberty, problems in the family or with peers, trauma, and personality traits such as low self-esteem. It is characterized by extreme food restriction and an intense fear of gaining weight. Treatment usually involves several strategies, including psychological therapy, nutritional counseling, and/or hospitalization.
Treatment plans are tailored to individual needs and may include one or more of the following:
• The individual, group, and/or family psychotherapy
• Medical care and monitoring
• Nutritional counseling
• Medications
Psychotherapies generally include Family-based treatment (FBT), Eating disorder-focused, Adolescent-focused psychotherapy, and others
Medications such as antidepressants, antipsychotics, or mood stabilizers may also be helpful for the treatment of eating disorders and other co-occurring illnesses such as anxiety or depression. Medications like olanzapine, aripiprazole, and dronabinol are generally used to manage the patients, but there is no standard therapy available. Quetiapine is an atypical antipsychotic that, in low dose, can help with both psychological and physical improvements, with minimal associated side effects, and appears to be a promising candidate for the treatment of AN. Prozac can help with depressive symptoms and potentially with healthy weight maintenance once weight restoration is achieved. Prozac is part of the SSRI family or the selective serotonin uptake inhibitors that assist with increased serotonin levels connected to mood.

Key Findings
• The market size of anorexia nervosa in seven major markets was USD 63 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 18.9 % for the study period (2019–2032)
• The expected launch of potential therapy may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of anorexia nervosa.
• Upcoming therapy such as Psilocybin has the potential to create a significant positive shift in the anorexia nervosa market size.
• The United States accounts for the largest market size of Anorexia nervosa, in comparison to EU5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.

The United States Market Outlook
This section provides the total anorexia nervosa market size and market size by therapies in the United States.

EU-5 Market Outlook
The total anorexia nervosa market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook
The total anorexia nervosa market size and market size by therapies in Japan are provided.

Anorexia nervosa Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the anorexia nervosa market or expected to get launched in the market during the study period 2019–2032. The analysis covers the anorexia nervosa market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Anorexia nervosa Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stages also analyze key players involved in developing targeted therapeutics.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for anorexia nervosa emerging therapies.
Reimbursement Scenario in Anorexia nervosa
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis
We perform competitively and market Intelligence analysis of the anorexia nervosa market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
• The report covers the descriptive overview of anorexia nervosa, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
• Comprehensive insight has been provided into the anorexia nervosa epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for anorexia nervosa is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the anorexia nervosa market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Anorexia nervosa market.

Report Highlights
• The robust pipeline with novel MOA and oral ROA and increasing diagnosed prevalence will positively drive the anorexia nervosa market.
• The companies and academics are working to assess challenges and seek opportunities that could influence anorexia nervosa R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for anorexia nervosa. The launch of emerging therapies will significantly impact the anorexia nervosa market.
• Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Anorexia nervosa Report Insights
• Patient Population
• Therapeutic Approaches
• Anorexia nervosa Pipeline Analysis
• Anorexia nervosa Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Anorexia nervosa Report Key Strengths
• 11-Years Forecast
• The 7MM Coverage
• Anorexia nervosa Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market

• Drugs Uptake

Anorexia nervosa Report Assessment
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• SWOT analysis

Key Questions

Market Insights:
• What was the anorexia nervosa market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the anorexia nervosa total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest anorexia nervosa market size during the forecast period (2022–2032)?
• At what CAGR, the anorexia nervosa market is expected to grow at the 7MM level during the forecast period (2022–2032)?
• What would be the anorexia nervosa market outlook across the 7MM during the forecast period (2022–2032)?
• What would be the anorexia nervosa market growth till 2032 and what will be the resultant market size in the year 2032?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:
• What is the disease risk, burden, and unmet needs of anorexia nervosa?
• What is the historical anorexia nervosa patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of anorexia nervosa at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to anorexia nervosa?
• Out of the above-mentioned countries, which country would have the highest population of anorexia nervosa during the forecast period (2022–2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
• What are the current options for the treatment of anorexia nervosa along with the approved therapy?
• What are the current treatment guidelines for the treatment of anorexia nervosa in the US and Europe?
• What are the anorexia nervosa marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of anorexia nervosa?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of anorexia nervosa?
• What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, licensing activities related to the Anorexia nervosa therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for anorexia nervosa and their status?
• What are the key designations that have been granted for the emerging therapies for anorexia nervosa?
• What are the 7MM historical and forecasted market of anorexia nervosa?

Reasons to buy
• The report will help in developing business strategies by understanding trends shaping and driving anorexia nervosa.
• To understand the future market competition in the anorexia nervosa market and an Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for anorexia nervosa in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the anorexia nervosa market.
• To understand the future market competition in the anorexia nervosa market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on